Security Snapshot

CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX) Institutional Ownership

CUSIP: 14888U101

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

371

Shares (Excl. Options)

103,955,151

Price

$23.34

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
CPRX on Nasdaq
Shares outstanding
123,180,519
Price per share
$24.94
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
103,955,151
Total reported value
$2,424,463,907
% of total 13F portfolios
0%
Share change
-206,156
Value change
+$6,403,139
Number of holders
371
Price from insider filings
$24.94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CPRX - CATALYST PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 14888U101.
  • 371 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 371 to 100 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,424,463,907 to $110,916,150.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 371 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 14888U101?
CUSIP 14888U101 identifies CPRX - CATALYST PHARMACEUTICALS, INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% $399,180,432 16,892,951 BlackRock, Inc. 31 Mar 2025
STATE STREET CORP 5.2% $126,186,124 6,405,387 STATE STREET CORPORATION 30 Sep 2025
Flynn James E 2.6% $74,033,050 3,133,011 Deerfield Mgmt, L.P. 31 Dec 2024

As of 31 Dec 2025, 371 institutional investors reported holding 103,955,151 shares of CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX). This represents 84% of the company’s total 123,180,519 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 18,626,781 +2.3% 0.01% $434,749,068
VANGUARD GROUP INC 6.8% 8,432,247 -3.2% 0% $196,808,646
STATE STREET CORP 5.6% 6,907,622 +7.8% 0.01% $161,223,897
DEERFIELD MANAGEMENT COMPANY, L.P. 4% 4,911,161 -1.3% 1.5% $114,626,498
Fundsmith LLP 2.7% 3,363,807 0% 0.46% $78,511,255
AMERICAN CENTURY COMPANIES INC 2.5% 3,025,271 +20% 0.04% $70,609,825
DIMENSIONAL FUND ADVISORS LP 2.4% 2,996,297 +22% 0.01% $69,932,608
MORGAN STANLEY 2.4% 2,933,399 +59% 0% $68,465,565
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,900,337 +0.35% 0% $67,704,365
RENAISSANCE TECHNOLOGIES LLC 2.2% 2,650,077 -25% 0.1% $61,852,797
BANK OF AMERICA CORP /DE/ 1.8% 2,199,842 -4% 0% $51,344,312
ROYCE & ASSOCIATES LP 1.6% 1,910,767 -6.1% 0.45% $44,597,302
JANUS HENDERSON GROUP PLC 1.4% 1,719,767 +201% 0.02% $40,123,723
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.3% 1,617,208 +24% 0.02% $37,745,635
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 1,356,499 +1.8% 0% $31,660,687
Invesco Ltd. 1.1% 1,293,478 +4.9% 0% $30,189,776
Boston Partners 1% 1,231,372 -4.6% 0.03% $28,539,969
NORTHERN TRUST CORP 0.98% 1,211,973 -4.1% 0% $28,287,449
KENNEDY CAPITAL MANAGEMENT LLC 0.98% 1,209,692 +14% 0.6% $28,234,211
MILLENNIUM MANAGEMENT LLC 0.81% 993,647 -16% 0.02% $23,191,721
GOLDMAN SACHS GROUP INC 0.8% 979,543 -2.7% 0% $22,862,534
VICTORY CAPITAL MANAGEMENT INC 0.72% 884,605 +112% 0.01% $20,646,681
RAYMOND JAMES FINANCIAL INC 0.68% 841,914 +8.9% 0.01% $19,624,682
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.63% 778,591 0% 0.03% $18,172,000
Legal & General Group Plc 0.63% 776,172 +0.27% 0% $18,115,855

Institutional Holders of CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 4,480,005 $110,916,150 -$3,980,308 $24.76 100
2025 Q4 103,955,151 $2,424,463,907 +$6,403,139 $23.34 371
2025 Q3 103,323,297 $2,035,619,506 +$33,916,547 $19.70 357
2025 Q2 101,339,025 $2,199,165,165 +$74,610,948 $21.70 360
2025 Q1 97,995,812 $2,374,736,976 +$45,703,179 $24.25 365
2024 Q4 97,462,582 $2,034,900,504 +$38,258,566 $20.87 333
2024 Q3 95,380,838 $1,896,646,482 -$35,292,712 $19.88 312
2024 Q2 96,983,113 $1,502,403,827 +$11,987,767 $15.49 269
2024 Q1 96,270,213 $1,534,339,181 +$191,142,132 $15.94 268
2023 Q4 84,453,649 $1,419,515,333 +$62,962,605 $16.81 259
2023 Q3 81,157,485 $948,788,519 -$23,397,502 $11.69 254
2023 Q2 82,218,793 $1,104,943,728 -$95,298,712 $13.44 243
2023 Q1 88,787,264 $1,472,124,820 +$71,196,268 $16.58 256
2022 Q4 84,107,036 $1,564,456,429 -$12,268,287 $18.60 252
2022 Q3 85,176,091 $1,093,105,879 +$187,635,691 $12.83 220
2022 Q2 75,651,199 $530,307,280 +$37,811,777 $7.01 175
2022 Q1 70,838,632 $586,598,135 +$41,265,648 $8.29 181
2021 Q4 66,018,446 $446,683,816 +$3,690,649 $6.77 160
2021 Q3 65,162,167 $345,106,769 -$2,224,745 $5.30 138
2021 Q2 65,482,202 $376,526,274 -$10,746,528 $5.75 137
2021 Q1 67,671,701 $311,885,548 +$10,809,324 $4.61 130
2020 Q4 66,576,359 $222,408,153 -$12,651,094 $3.34 131
2020 Q3 67,907,092 $201,992,589 +$603,491 $2.97 140
2020 Q2 64,719,712 $299,102,386 -$2,974,113 $4.62 138
2020 Q1 65,840,014 $253,546,747 +$11,634,204 $3.85 128
2019 Q4 62,834,633 $235,638,867 -$30,765,313 $3.75 127
2019 Q3 61,617,508 $327,170,529 +$8,126,558 $5.31 117
2019 Q2 61,553,639 $236,256,732 -$4,762,099 $3.84 99
2019 Q1 61,491,932 $313,611,586 +$64,665,968 $5.10 87
2018 Q4 49,136,126 $94,337,873 -$22,145,979 $1.92 85
2018 Q3 51,043,397 $192,937,538 -$11,273,654 $3.78 96
2018 Q2 54,196,334 $169,201,579 +$2,782,969 $3.12 98
2018 Q1 54,723,682 $130,787,787 -$11,120,389 $2.39 97
2017 Q4 56,055,280 $219,183,091 +$80,363,139 $3.91 105
2017 Q3 35,604,156 $89,681,592 +$4,372,606 $2.52 77
2017 Q2 33,946,250 $93,689,694 +$24,746,037 $2.76 68
2017 Q1 25,299,931 $49,329,000 +$4,788,629 $1.95 51
2016 Q4 23,812,013 $25,000,000 +$512,936 $1.05 51
2016 Q3 23,293,467 $25,386,000 -$1,705,125 $1.09 46
2016 Q2 25,351,615 $17,997,000 -$12,327,656 $0.71 57
2016 Q1 36,952,362 $43,231,000 -$15,825,279 $1.17 73
2015 Q4 42,424,296 $103,944,627 -$6,424,568 $2.45 86
2015 Q3 44,724,461 $134,180,687 +$3,442,159 $3.00 88
2015 Q2 43,473,000 $179,861,198 +$18,861,290 $4.13 86
2015 Q1 38,864,127 $168,166,940 +$54,418,957 $4.33 64
2014 Q4 27,360,884 $81,277,000 +$8,330,747 $2.97 49
2014 Q3 23,623,262 $78,388,100 +$8,077,982 $3.32 51
2014 Q2 22,284,591 $56,380,420 +$29,950,485 $2.53 46
2014 Q1 10,454,712 $23,627,120 +$2,788,485 $2.26 36
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .